Minerva Neurosciences, INC 8-K filings

Minerva Neurosciences, Inc. announced the appointment of Anthony Aliquo as Chief Accounting Officer, effective August 10, 2026, with adjustments to his compensation.

Minerva Neurosciences reported second quarter 2026 financial results and business updates, highlighting ongoing Phase 3 trial progress for roluperidone while financial performance was significantly impacted by non-cash warrant liability adjustments.

Minerva Neurosciences' stockholders approved amendments to the company's charter and bylaws at the 2026 Annual Meeting, impacting officer liability, forum selection, and meeting procedures.

Minerva Neurosciences has entered into a Sales Agreement for an at-the-market offering program, potentially raising up to $75 million, while also updating its Phase 3 schizophrenia trial timeline.

Minerva Neurosciences reported Q1 2026 financial results, highlighting the initiation of its Phase 3 trial for roluperidone for negative schizophrenia symptoms and a significant increase in R&D and G&A expenses.

Minerva Neurosciences announced its 2026 annual meeting of stockholders will be held on June 3, 2026, with specific deadlines for stockholder proposals and nominations.

Minerva Neurosciences announced further details regarding its planned confirmatory Phase 3 trial for roluperidone in schizophrenia, with initiation expected in Q2 2026.

Minerva Neurosciences' stockholders approved a significant increase in authorized common stock and equity incentive plan shares, alongside director elections and auditor ratification at its 2025 Annual Meeting.

Minerva Neurosciences strengthens its Board and clinical development expertise with the appointment of Dr. Inderjit Kaul, a seasoned drug development leader, and engages him as a consultant for roluperidone's Phase 3 trial.

Minerva Neurosciences announced a private placement of up to $200 million to fund its Phase 3 confirmatory trial for roluperidone in schizophrenia and prepare for NDA resubmission and commercial launch.

Minerva Neurosciences has been notified by Nasdaq that it has regained compliance with the Net Income Rule, ensuring continued listing, but will be subject to a one-year monitoring period.

Minerva Neurosciences has received an extension from Nasdaq to maintain its listing, contingent on meeting specific financial and disclosure requirements by March 31, 2025.

Minerva Neurosciences held its 2024 Annual Meeting of Stockholders on December 5, 2024, where directors were elected, executive compensation was approved, and the company's auditor was ratified.

Minerva Neurosciences has received a second delisting notice from Nasdaq due to its failure to maintain the minimum market value of listed securities, and the company intends to request a hearing to appeal the decision.

Minerva Neurosciences has scheduled its 2024 annual meeting for December 5, 2024, and established an October 1, 2024 deadline for stockholder proposals and director nominations.

Minerva Neurosciences reports the resignation of Jeryl Hilleman from the Board and Audit Committee, effective August 6, 2024, with Jan van Heek appointed as the new Audit Committee Chair and Dr. David Kupfer as a new member.

Minerva Neurosciences has received a notice from Nasdaq for failing to maintain the minimum market value of listed securities, putting the company at risk of delisting.

The FDA issued a Complete Response Letter to Minerva Neurosciences, rejecting their New Drug Application for roluperidone to treat negative symptoms of schizophrenia, citing clinical deficiencies.